Literature DB >> 11910316

Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study).

Jacques Amar1, Laurent Vaur, Marc Perret, Christine Bailleau, Sylvie Etienne, Bernard Chamontin.   

Abstract

OBJECTIVE: To determine whether blood pressure control in a general practice setting is influenced by the presence of additional risk factors, and to analyse the role of antihypertensive therapy in this relationship.
DESIGN: A cross-sectional study was conducted with a sample of 3153 general practitioners.
SETTING: Primary care. PARTICIPANTS: The first five hypertensive patients presenting at the practitioner's office were included. MAIN OUTCOME MEASURES: Cardiovascular risk factors, antihypertensive drugs and cardiovascular history were reported. Blood pressure was measured. The analysis was conducted in treated patients who were divided in three groups: no other risk factors (group I); 1-2 risk factors (group II); 3 or more risk factors or target-organ damage or diabetes or associated cardiovascular disease (group III).
RESULTS: Data were available for all variables in the 14 066 treated hypertensive individuals who form the basis of this report. Blood pressure control had been achieved in a lower percentage of individuals in group III (27%) than in group I (42.9%). To control hypertension, combination therapies were more frequently required in group III (55.8%) than in group II (43.5%) or group I (34.2%). Among individuals with uncontrolled hypertension, about 39% of patients in group III were receiving monotherapy and the percentage receiving two-drug treatments identified as effective in the 1999 WHO guidelines was significantly lower in group III.
CONCLUSION: The study shows that, in general practice, control of blood pressure decreases as the number of risk factors present increases. An underuse of combination therapy, especially effective two-drug treatment in patients with several risk factors, may account for this finding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11910316     DOI: 10.1097/00004872-200204000-00038

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  12 in total

Review 1.  Combination pharmacotherapy in hypertension.

Authors:  George S Stergiou
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction.

Authors:  Andrea B Parker; C David Naylor; Alice Chong; David A Alter
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

4.  Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2010-05-10

5.  Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.

Authors:  Daria Roccatagliata; Fausto Avanzini; Lara Monesi; Vittorio Caimi; Davide Lauri; Paolo Longoni; Roberto Marchioli; Massimo Tombesi; Gianni Tognoni; Maria Carla Roncaglioni
Journal:  Vasc Health Risk Manag       Date:  2006

6.  The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.

Authors:  Joel M Neutel; Elijah Saunders; George L Bakris; William C Cushman; Keith C Ferdinand; Elizabeth O Ofili; James R Sowers; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-10       Impact factor: 3.738

7.  Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.

Authors:  Claudio Borghi; Francesca Santi
Journal:  Patient Prefer Adherence       Date:  2012-06-18       Impact factor: 2.711

8.  Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial.

Authors:  Jean-Jacques Mourad; Viet Nguyen; Marilucy Lopez-Sublet; Bernard Waeber
Journal:  Vasc Health Risk Manag       Date:  2007

Review 9.  Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.

Authors:  Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Suzanne Oparil; Aud Høieggen; Ingrid Os
Journal:  Vasc Health Risk Manag       Date:  2007

Review 10.  Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.

Authors:  H Haller
Journal:  Int J Clin Pract       Date:  2008-03-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.